Reimbursed Care Access in Papua New Guinea

Currently classified as a strictly controlled substance under international scheduling and national practice with no authorized medical use outside of approved clinical research. Citation: international scheduling of classical psychedelics under the 1971 Convention / psychotropic scheduling #; Papua New Guinea enforces restrictive controls via national narcotics enforcement and health regulatory practice (see national narcotics contact listing). #

Currently classified as a strictly controlled substance under international scheduling and national practice with no authorized medical use outside of approved clinical research. Citation: international scheduling of MDMA under the 1971 Convention / psychotropic scheduling #; PNG enforces controls consistent with the Convention through its national narcotics structures. #

There is no publicly available evidence of a national regulatory listing or reimbursement pathway for esketamine (Spravato) in Papua New Guinea; it is not documented on PNG national medicine/essential medicine lists and is not known to be in routine clinical use or reimbursed. Where esketamine is used in other jurisdictions it requires specific product registration and supervised administration; in PNG the available data indicate no routine national approval and therefore any access would be limited to authorised clinical research or import on a case-by-case special access/compassionate basis (if granted by national regulators). For context, ketamine (the racemate) is listed on the WHO Model List of Essential Medicines as an injectable anaesthetic #; absence of esketamine registration in PNG is reflected in national medicine listings and the absence of published regulatory approval documents. For PNG narcotics/medicines contact information see the National Narcotics Bureau listing. #

Ketamine is an established, routinely used anaesthetic and analgesic in Papua New Guinea’s healthcare system and is included on the WHO Model List of Essential Medicines as an injectable anaesthetic. #

Clinical/health system evidence documents routine local use: facility surveys and service-capacity studies of PNG hospitals and district facilities report ketamine use for anaesthesia and procedural sedation across national, provincial and many district hospitals (ketamine is frequently the principal anaesthetic available outside major referral centres). This indicates established medical availability in public and private hospital settings, but reimbursement and supply are constrained by PNG’s broader medicine procurement and health-funding challenges; supply interruptions and shortages of essential medicines are periodically reported and can affect availability at provincial and district levels. # #

Regulatory and payer nuance: ketamine functions as a registered medicinal anaesthetic in most health systems and in PNG is used clinically within hospitals (public and private). Public financing and reimbursement for medicines in PNG is limited and unevenly distributed across provinces; therefore ketamine is usually supplied as part of hospital medicines procurement rather than via an outpatient reimbursed prescription program. Recent PNG health-system reports highlight intermittent stock and procurement challenges that can interrupt access at provincial/district levels. #

Currently classified as a strictly controlled substance under international scheduling (DMT is listed under the 1971 Convention) and, in practice, is not authorised for medical use in PNG outside approved clinical research. Note that ayahuasca preparations contain DMT but their legal status follows domestic interpretation of DMT scheduling; in PNG there is no documented national medical pathway for DMT-containing traditional brews. # #

Currently classified as a strictly controlled substance under national drug scheduling practice and international conventions in effect; there is no authorised medical use in PNG outside approved clinical research. # #

Currently classified as a strictly controlled substance under national drug scheduling practice with no authorised medical use outside approved clinical research in PNG. There is no evidence of any regulated medical or reimbursed access pathway for ibogaine in PNG. # #

Ayahuasca preparations contain DMT, which is controlled internationally; in PNG there is no recognised medical or reimbursed access pathway for ayahuasca beyond authorised research or potentially narrow religious exemptions (none documented). Therefore ayahuasca use falls under the same restrictive controls applied to DMT in national practice. # #

Currently classified as a strictly controlled substance under international scheduling and national practice with no authorised medical use in PNG outside approved clinical research. Traditional cactus preparations containing mescaline are not documented as having legal medical status or reimbursement in PNG. # #

Currently classified and treated as an illicit/controlled class of substituted phenethylamine/psychedelic compounds under national drug enforcement practice with no authorised medical use or reimbursement in PNG outside approved clinical research. 2C-series compounds are controlled in most jurisdictions under psychotropic scheduling and PNG enforces restrictive controls in line with international conventions. # #